Royalty Pharma RPRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $630.58M+1.4% | $621.99M+2.1% | $609.29M+5.3% | $578.67M+1.8% | $568.25M-4.3% | ||
| $39.79M-21.2% | $50.5M0.0% | $50.5M-83.2% | $300.5M+495% | $50.5M+10,000% | ||
| $159.49M-2.9% | $164.27M+38.4% | $118.73M-34.0% | $179.77M+62.4% | $110.71M+63.8% | ||
| $67.54M-71.1% | $233.61M+28.3% | $182.14M-50.6% | $368.87M+983% | $34.07M-85.3% | ||
| $563.04M+45.0% | $388.38M-9.1% | $427.16M+104% | $209.8M-60.7% | $534.18M+47.8% | ||
| 89.3%+26.8pp | 62.4%-7.7pp | 70.1%+33.9pp | 36.3%-57.7pp | 94%+33.1pp | ||
| $93.72M-0.5% | $94.17M+18.4% | $79.56M+15.9% | $68.67M+5.2% | $65.26M-0.8% | ||
| -$94.78M-192% | -$32.47M-290% | $17.06M+114% | -$119.16M-19.5% | -$99.75M— | ||
| $468.26M+31.6% | $355.91M-19.9% | $444.21M+390% | $90.64M-79.1% | $434.43M+29.9% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $294.69M+37.6% | $214.21M-25.7% | $288.22M+855% | $30.18M-87.4% | $239.35M+15.0% | ||
| 46.7%+12.3pp | 34.4%-12.9pp | 47.3%+42.1pp | 5.2%-36.9pp | 42.1%+7.0pp | ||
| $0.67+34.0% | $0.50-25.4% | $0.67+857% | $0.07-87.3% | $0.55+17.0% | ||
| $563.04M+45.0% | $388.38M-9.1% | $427.16M+104% | $209.8M-60.7% | $534.18M+47.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Royalty Pharma's revenue?
- Royalty Pharma (RPRX) generated $2.4B in revenue over the trailing twelve months, up 7.8% year over year.
- Is Royalty Pharma profitable?
- Royalty Pharma reported $827.3M in net income over the trailing twelve months, a 33.9% net margin.
- What is Royalty Pharma's earnings per share?
- Royalty Pharma's diluted EPS over the trailing twelve months is $1.91.
- Where does Royalty Pharma's income statement data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
